English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Dopamine (DA) receptor (D1 and D2-like receptors) agonists are known to affect expression levels of DA receptors. Rotigotine, a DA D2-like receptor agonist, has been developed for treating Parkinson’s disease (PD). However, its role in PD by acting through DA D2-like receptors has not been fully understood yet. The purpose of this study was to investigate neuroprotective effects of rotigotine through DA D2 and D3 receptors in 6-hydroxydopamine (6-OHDA) induced mouse model of PD. Expression level of tyrosine hydroxylase (TH) was examined using immunohistochemistry and Western blot analysis. Results revealed that unilateral injection of 6-OHDA into the midbrain caused significant loss of TH positive cells in the substantia nigra, whereas rotigotine inhibited such loss of TH cells in 6-OHDA-induced mouse model of PD. In vitro experiments demonstrated that rotigotine increased expression levels of TH against 6-OHDA-induced toxicity. The expression level of TH after treatment with L’741,626, a D2 receptor antagonist was decreased more than that after treatment with GR 103691, a D3 receptor antagonist. These results suggest that rotigotine can protect DA neurons against 6-OHDA induced toxicity and that the protective effect of rotigotine for DAergic neurons through a DA D2 receptor is stronger than that through a DA D3 receptor.

Rotigotine protects dopaminergic neurons through dopamine D2 receptor against 6-hydroxydopamine